It’s Any major hospital in Dubai or Riyadh has an atrium that is truly impressive, with polished marble floors, multinational staff moving through hallways with efficiency, and diagnostic equipment that most hospitals in the Midwest of the United States would envy. Over the past 20 years, the countries of the Gulf Cooperation Council have developed healthcare infrastructure at a rate that is unmatched in the contemporary world. In the Gulf Cooperation Council, life expectancy increased from 60.5 years in 1978 to 73 years in 2004. During the same time period, infant mortality decreased from 69 deaths per 1,000 live births to 18. These improvements are not insignificant. These are the kinds of figures that are used as illustrations of what concentrated investment can achieve quickly in development economics textbooks.
And yet. Nearly half of all children under five in Yemen are stunted due to malnutrition, just a short flight from those shiny hospitals. In the same regional context as Saudi Arabia’s expanding capacity for targeted cancer therapies and budget impact analyses of HER2-positive breast cancer treatments, this statistic was revealed in a new research series that was published in the March 2026 issue of Value in Health Regional Issues. According to the researchers, the Gulf is part of a larger Middle East and North Africa region where wealth coexists with areas of vulnerability, conflict, and serious unmet health needs. This coexistence is not accidental. It is structural and determines what kind of advancements in healthcare are truly feasible.
| Topic | Healthcare Reform, Innovation, and Inequality in the Arabian Gulf and MENA Region |
|---|---|
| Key Publication | Value in Health Regional Issues — Special Themed Section, March 2026 |
| Published By | ISPOR — The Professional Society for Health Economics and Outcomes Research |
| Guest Editors | Paul Revill, Sara Al-Dallal, Anderson Stanciole |
| GCC Member Nations | Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates |
| GCC Healthcare Expenditure | Projected to reach $104.6 billion (2022) from $76.1 billion (2017) — 6.6% CAGR |
| Life Expectancy Progress | Rose from 60.5 years (1978) to 73 years (2004) across GCC |
| Infant Mortality Progress | Fell from 69 per 1,000 live births to 18 in the same period |
| Key Regional Disparity | Yemen: nearly 50% of children under 5 stunted; Saudi Arabia investing in targeted cancer therapies |
| Saudi Reform Focus | Generic medicine cost savings, schizophrenia burden, HER2-positive cancer treatment, value-based care transition |
| Jordan Issue Flagged | Declining maternal mortality masks persistent economic burden — especially among women in prime working years |
| Reference Links | ISPOR – Progress and Paradox: Healthcare Reform in the Arabian Gulf / World Economic Forum – How Can the Gulf’s Health Systems Adapt |
The research series, which consists of nine papers arranged into three thematic areas and guest-edited by Paul Revill, Sara Al-Dallal, and Anderson Stanciole, is the most thorough recent effort to map value-based healthcare throughout the GCC and the larger MENA region. The papers cover a wide range of topics, from the potential of tiered food and beverage taxation to lower diet-driven noncommunicable disease to the economic burden of schizophrenia in Saudi Arabia to mortality trends throughout the Middle East and North Africa. When taken as a whole, they paint a picture of a region that is truly undergoing change, albeit at very different rates for various populations and with a persistent gap between expensive innovation and unfulfilled basic needs.
A significant portion of the first thematic cluster is occupied by Saudi Arabia, and the resulting image is genuinely complex. The Kingdom is actively discussing the cost-effectiveness of medications like fam-trastuzumab-deruxtecan for metastatic breast cancer and has the financial capacity to pursue targeted cancer therapies. Simultaneously, a different study details the financial and social toll that schizophrenia takes on patients and their families. Schizophrenia is a condition that frequently necessitates long-term medication management and community support, not the kind of high-profile innovation that produces conference keynote addresses. Despite the potential cost savings, generic medications are still underutilized in a system that is still trying to strike a balance between affordability and innovation. These tales don’t contradict one another. The healthcare system is the same, but it operates at different elevations.
The Gulf’s paradox is reflected in Jordan’s maternal mortality statistics. The headline is that Jordan’s maternal mortality rate has decreased. However, a 2026 paper in the series discovered that the economic burden of maternal death is still significant, with significant geographic and social variation, and it primarily affects women in their prime working and caregiving years. The paper’s framing of maternal mortality as an economic burden—in terms of lost productivity, lost caregiving, and lost income—captures something that mortality statistics alone tend to miss, and declining death rates do not always translate into equitable outcomes. A declining number does not always indicate that the underlying issue has been resolved.
The nutrition findings from Yemen should be given more consideration than they typically receive when talking about healthcare in the Gulf. The series included a benefit-cost analysis that looked at the benefits of increasing nutrition interventions in a nation where stunting affects almost half of children under five. Significant returns are suggested by the intervention modeling. The research wisely does not pretend otherwise because the logistical and political realities of implementing those interventions in an active conflict zone are quite different. However, it documents the extent of unaddressed issues and the cost of that disparity, as seen in children whose early malnutrition is permanently altering their cognitive and physical development.
Reading through these nine papers gives the impression that the region’s health economists are attempting to accomplish something truly beneficial: creating the body of evidence necessary for policymakers to make more informed decisions about where health spending is most beneficial. The editors advocate for more institutional integration of that evidence into actual policy and for ongoing funding for health technology assessment, which is the formal process of determining whether a particular treatment or intervention truly justifies its cost. It sounds like a procedure. In actuality, it is the distinction between a system that distributes resources according to political visibility and one that does so according to what best serves the greatest number of people.
The GCC was expected to spend $104.6 billion on healthcare in 2022, increasing at a rate of more than 6% per year. That is a significant amount, and it is yielding tangible outcomes, such as new hospitals, increased specialty care, and increased capacity for treatments that were not available in the area ten years ago. Whether the institutional frameworks are in place to guarantee that spending results in proportionate health outcomes rather than disproportionately concentrating benefit among populations already well-served is still up for debate. Funding is not the main cause of the disparity between the atrium in Dubai and the stunted child in Yemen. It is more difficult to close the distributional, governance, and priority gaps with just capital expenditures.
